[Form 4] Oncology Institute, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) reported a Form 4 for director Brad Hively11/20/2025. The filing shows two grants of common stock in the form of restricted stock units at a price of $0 per share. One grant for 41,667 shares consists of restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service through that date. A second grant for 32,407 shares consists of restricted stock units that were fully vested upon grant. Following these transactions, Hively beneficially owns 697,054 shares of common stock directly.

11/24/2025 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hively Brad

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		41,667(1)	A	$0	664,647	D
Common Stock	11/20/2025		A		32,407(2)	A	$0	697,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date.

2. Represents restricted stock units that were fully vested upon grant.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Oncology Institute (TOI) report in this Form 4 filing?

The Form 4 reports equity awards to director Brad Hively in the form of restricted stock units (RSUs) in Oncology Institute, Inc. common stock on 11/20/2025.

How many Oncology Institute (TOI) shares were granted to the director?

The director received restricted stock units covering 41,667 shares of common stock in one grant and 32,407 shares of common stock in a second grant.

What are the vesting terms of the new RSU awards reported for TOI?

One RSU award for 41,667 shares vests in full on the company’s 2026 annual stockholder meeting date, while the 32,407-share RSU award was fully vested upon grant.

What is the director’s total beneficial ownership in Oncology Institute (TOI) after these grants?

After the reported transactions, the director beneficially owns 697,054 shares of Oncology Institute, Inc. common stock in direct ownership.

Was any cash paid for the restricted stock units in this TOI Form 4?

The Form 4 shows a price of $0 for each share underlying the restricted stock units, indicating they were awarded without a cash purchase price.

What is the reporting person’s relationship to Oncology Institute (TOI)?

The reporting person is identified as a director of Oncology Institute, Inc. on the Form 4.